(Q37980497)

26 August 2017

title

Cardiovascular metabolic syndrome: mediators involved in the pathophysiology from obesity to coronary heart disease (English)

1 reference

26 August 2017

0 references

1 reference

1 reference

1 reference

3

J Wouter Jukema

1 reference

26 August 2017

Cornelis J Roos

1

1 reference

26 August 2017

Paul H A Quax

series ordinal

2

1 reference

26 August 2017

publication date

1 February 2012

1 reference

26 August 2017

published in

Biomarkers in Medicine

1 reference

26 August 2017

volume

6

1 reference

26 August 2017

issue

1

1 reference

26 August 2017

page(s)

35-52

1 reference

Global burden of obesity in 2005 and projections to 2030.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: A review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Predicting the risk of coronary heart disease I. The use of conventional risk markers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Predicting the risk of coronary heart disease. II: the role of novel molecular biomarkers and genetics in estimating risk, and the future of risk prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Inflammatory markers and cardiovascular risk in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adipose tissue dysfunction in obesity, diabetes, and vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Obesity, inflammation, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Cardiovascular metabolic syndrome - an interplay of, obesity, inflammation, diabetes and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adipose development: from stem cell to adipocyte

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

The role of chemokines in recruitment of immune cells to the artery wall and adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Diabetes, oxidative stress, and antioxidants: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Nitric oxide deficiency as a cause of clinical hypertension: promising new drug targets for refractory hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

NO/peroxynitrite dynamics of high glucose-exposed HUVECs: chemiluminescent measurement and computational model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Modulating an oxidative-inflammatory cascade: potential new treatment strategy for improving glucose metabolism, insulin resistance, and vascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Mechanisms of fatty acid-induced inhibition of glucose uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Contribution of adipose triglyceride lipase and hormone-sensitive lipase to lipolysis in hMADS adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Tumor necrosis factor-alpha inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Platelet inhibition by insulin is absent in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Platelet NAD(P)H-oxidase-generated ROS production regulates alphaIIbbeta3-integrin activation independent of the NO/cGMP pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Perivascular adipose tissue and its role in type 2 diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

"Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Oxidized phospholipids: biomarker for cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Scavenger receptors in innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adiponectin: more than just another fat cell hormone?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adiponectin and development of type 2 diabetes in the Pima Indian population

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Plasma adiponectin levels and risk of myocardial infarction in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adiponectin and future coronary heart disease events among men with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Pharmacogenetics of leptin in antipsychotic-associated weight gain and obesity-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Leptin and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

21 January 2018

Leptin and Inflammation

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

High serum leptin is associated with attenuated coronary vasoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Association of circulating levels of leptin and adiponectin with metabolic syndrome and coronary heart disease in patients with various coronary risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Leptin predicts the development of diabetes in Mauritian men, but not women: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Leptin and coronary heart disease: prospective study and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Hyperleptinemia as a robust risk factor of coronary artery disease and metabolic syndrome in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

C-reactive protein and incident cardiovascular events among men with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

C-reactive protein is a bystander of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Human C-reactive protein and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Human C-reactive protein does not promote atherosclerosis in transgenic rabbits.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

The effect of including C-reactive protein in cardiovascular risk prediction models for women.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Muscle as an endocrine organ: focus on muscle-derived interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Inflammatory markers and risk of developing type 2 diabetes in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Inflammatory markers and the risk of coronary heart disease in men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Rates and determinants of coronary and abdominal aortic artery calcium progression in the Veterans Affairs Diabetes Trial (VADT).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

(Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Positive and negative regulation of insulin signaling through IRS-1 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Tumor necrosis factor alpha inhibits signaling from the insulin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Tumor necrosis factor-alpha induces endothelial dysfunction in Lepr(db) mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Inflammation, the metabolic syndrome, and risk of coronary heart disease in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Tumor necrosis factor-alpha receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the Cytokine-Activation and Long-Term Prognosis in Myocardial Infarction (C-ALPHA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Inflammatory markers and onset of cardiovascular events: results from the Health ABC study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Chemokines and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Chemokines and atherosclerotic plaque progression: towards therapeutic targeting?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Chemokines in atherosclerosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Systemic chemokine levels, coronary heart disease, and ischemic stroke events: the PRIME study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Chemokine ligand 2 genetic variants, serum monocyte chemoattractant protein-1 levels, and the risk of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Lipoprotein-associated phospholipase A₂ activity predicts progression of subclinical coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Lipoprotein-associated phospholipase A2 activity and incident coronary heart disease among men and women with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Considering TWEAK as a target for therapy in renal and vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Tumor necrosis factor-like weak inducer of apoptosis attenuates the action of insulin in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Pentraxins in innate immunity: lessons from PTX3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Pentraxins, anti-pentraxin antibodies, and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Plasma PTX3 protein levels inversely correlate with insulin secretion and obesity, whereas visceral adipose tissue PTX3 gene expression is increased in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Adiponectin and Coronary Heart Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Plasma Leptin Levels Are Associated with Coronary Atherosclerosis in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: Results from the ESTHER study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Establishment of a High Sensitivity Plasma Assay for Human Pentraxin3 as a Marker for Unstable Angina Pectoris

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

TNF-α induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-γ agonist pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

Determinants of Progression of Coronary Artery Calcification in Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FBMM.11.105

21 January 2018

Identifiers

DOI

10.2217/BMM.11.105

1 reference

26 August 2017

1 reference